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Introduction
The analogy of cells as tiny machines has captured the attention 
and imagination of scientists from many disciplines, leading to 
the emergence of a research field known as synthetic biology. 
Synthetic biology encompasses a range of endeavors, such as 
chemical systems that mimic living systems (for review see 
Benner and Sismour 2005), novel functional assemblies of 
natural molecular components, simplified cells, and artificial 
ecosystems (for review see Purnick and Weiss, 2009). More 
conventional research disciplines define functions and inter­
actions of cellular components based on the results of experiments 
where individual parts are perturbed or over­produced within a 
natural system or in vitro. Molecular characterizations are further 
supported by evolutionary studies that identify conserved motifs 
and by structural studies that reveal relationships between 
molecular shape and function. Synthetic biology applies this 
knowledge to rationally design and construct biological net­
works of interacting modules. Testing custom­built pathways in 
living cells provides a unique opportunity to observe the behav­
ior of biological components in new contexts, revealing the ex­
tent of our understanding of natural systems.
Another integral aspect of synthetic biology is its relation­
ship  with  mathematical  modeling.  Equations  and  computer 
simulations that model relationships between biological pro­
cesses (e.g., gene activation, protein production, cell division, 
etc.) guide the design of synthetic systems by determining the 
vital parameters and parameter spaces in which the system will 
function as intended. Biological modules are then assembled in 
a manner consistent with the model (Elowitz and Leibler, 2000; 
Gardner et al., 2000; Ajo­Franklin et al., 2007; Brenner et al., 
2007; Ellis et al., 2009). Once the assembly is tested and char­
acterized in a living system, empirical data can provide new 
parameters to improve the mathematical model. In this way, 
iterative cycles of modeling, building, and testing lead to useful 
synthetic systems and new insights into living mechanisms.
In this review, we focus on synthetic biology’s efforts to 
build novel biological pathways within single living cells. We 
use the term “synthetic circuit” or “synthetic device” to describe 
a system that is designed to execute a useful function (a bistable 
state, oscillation, pulse, etc.) in a predictable and reliable man­
ner. Of particular interest are basic extensible functions with 
implications for biotechnology and gene therapy. For instance, 
a genetic toggle switch that responds to transient input signals, 
similar to how a lamp responds to a mechanical “on/off” switch, 
would allow long­term maintenance of protein expression with­
out sustained drug administration. A simple bistable switch can 
be built using two mutually repressive genes (Fig. 1 A). When 
each gene encodes a transcriptional repressor of the other and 
each repressor is blocked by a chemical input, the system can be 
switched between two stable states (i.e., “gene 1 on, gene 2 off” 
vs. “gene 1 off, gene 2 on”). Gardner et al. (2000) used mathe­
matical modeling to predict that bistability is possible with any 
set of promoters or repressors as long as they fulfill a minimum 
set of conditions (e.g., balanced promoter strengths). Using these 
predictions, they constructed and successfully operated a toggle 
switch in Escherichia coli (Fig. 1 B). Four years later, Kramer   
et al. (2004) reported that a similar device could be operated within 
a eukaryotic system (Chinese hamster ovary cells; Fig. 1 C).
To generate devices that may be adapted to a variety of tasks, 
engineering principles such as modularity and standardization 
are applied to genetic construction. The mechanics of synthetic 
Synthetic biology aims to engineer novel cellular functions 
by assembling well-characterized molecular parts (i.e., 
nucleic acids and proteins) into biological “devices” that 
exhibit predictable behavior. Recently, efforts in eukary-
otic synthetic biology have sprung from foundational work 
in bacteria. Designing synthetic circuits to operate reliably 
in the context of differentiating and morphologically com-
plex cells presents unique challenges and opportunities 
for progress in the field. This review surveys recent ad-
vances in eukaryotic synthetic biology and describes how 
synthetic systems can be linked to natural cellular pro-
cesses in order to manipulate cell behavior and to foster 
new discoveries in cell biology research.
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and plant cells. The following survey of eukaryotic synthetic 
devices is accompanied by a discussion of approaches that link 
synthetic systems with natural cellular cues and phenotypes. 
We then discuss how eukaryotic cell structure can be harnessed to 
broaden the field of synthetic biology. We conclude with a specu­
lation of synthetic biology’s contributions to cell biology research 
and medicine, as well as a discussion of current challenges of 
synthetic device engineering in eukaryotic systems.
Synthetic devices in eukaryotic cells
The first genetic circuits engineered in bacteria are elegant dem­
onstrations of how molecular biological processes can be ratio­
nally constructed from predefined parts. Prokaryotic synthetic 
circuits  have  provided  several  exciting  innovations,  including 
light­responsive  signal  transduction  systems  (Levskaya  et  al., 
2005) and oscillating transcription circuits (Elowitz and Leibler, 
2000). Are similar advances in eukaryotic synthetic systems pos­
sible given the largely uncharacterized and complex infrastructure 
of eukaryotic cells, potential perturbations, and cross talk with 
endogenous factors? Indeed, successes in manipulating preexist­
ing pathways and expressing synthetic gene networks in yeast, 
mammalian, and plant systems demonstrate the feasibility and 
usefulness of eukaryotic cells as platforms for synthetic biology.
Rewired  cell-signaling  pathways. Cell­signaling 
pathways carry information from external stimuli across the 
membrane and into the cell via a cascade of interactions be­
tween protein modules (for review see Bhattacharyya et al., 
2006).  Synthetic  biology  researchers  have  used  the  well­
characterized  mating  pheromone­induced  MAPK  signaling 
pathway from the budding yeast Saccharomyces cerevisiae to 
build and test synthetic auto­regulation. Ingolia and Murray 
(2007) placed a positive regulator of MAPK signaling under 
control of the MAPK signal cascade, creating a positive feed­
back loop that showed sustained output production after the 
stimulating pheromone was removed. A different approach 
used a modified membrane­associated Ste5 scaffold to acti­
vate gene expression of regulatory modules that either further 
induced or halted the MAPK signal cascade (Bashor et al., 2008). 
In the synthetic Ste5 systems, positive feedback changed sig­
nal output from a graded to a switch­like response, whereas 
negative feedback changed a sustained response to a pulsed 
or delayed response.
Engineered signal­processing cascades are circuit mod­
ules that can be linked to genetic and physiological outputs. 
The  synthetic  Ste5  MAPK  signaling  circuit  (Bashor  et  al., 
2008) could potentially regulate any gene of interest that is 
placed under control of the FUS1 promoter. Likewise, a plant 
system in which a Pho promoter is targeted by a histidine 
kinase­activated  PhoB­VP64  transcription  factor  provides  a 
means for linking cell signaling to gene transcription (Antunes 
et al., 2009). Physiological responses have been placed under 
the control of synthetic Fus3 and Hog1 MAPK proteins such 
that a pheromone input signal led to a hyper­osmolar response 
(and vice­versa) in yeast (Mody et al., 2009).
The sensor level of function in signaling circuits can be cus­
tomized using engineered receptors that specifically bind distinct 
input signals. Early work in which the human G protein–coupled 
devices can be summarized as a three­level hierarchy of inter­
changeable functions (Fig. 2 A). A signal (e.g., a small molecule) 
is detected at the sensor level, the signal is then processed into a 
pattern of behavior at the circuit level, and expression of a re­
porter gene coincides with the behavior of the circuit at the out­
put level. The overall design can be complex, containing multiple 
genes or proteins at each level of function (Fig. 2, B and C), or as 
simple as a single molecule that contains all three levels of func­
tion  (Fig.  2  D).  Step­wise  progress  in  synthetic  biology  has 
yielded many advances that are focused on individual levels of 
function rather than a complete system. To illustrate how these 
engineering developments might be integrated into complete sys­
tems in the future, this review presents each within the frame­
work of the sensor, circuit, and output levels of function.
To date, advances in synthetic biology are largely repre­
sented  by  experiments  in  bacterial  systems  (for  reviews  see 
Sprinzak and Elowitz 2005; Drubin et al., 2007). The cytological 
simplicity and well­defined components of the bacterial cell make 
it an attractive system for operating synthetic circuits. Recently, 
however, synthetic biology researchers have developed devices that 
function successfully in structurally complex yeast, mammalian, 
Figure 1.  Synthetic genetic toggle switches. (A) A genetic toggle switch 
comprised of two genes (Repressor A and Repressor B) encoding repressor 
proteins (RA and RB) uses a mutual repression motif to achieve bistability. 
Transient exposure to Input 1 inhibits RB and switches the system’s stable 
state to Repressor A expression. Input 2 inhibits RA and activates Repressor 
B and a detectable output (Reporter). (B) Stable GFP output from a synthetic 
prokaryotic toggle switch is activated by isopropyl--d-thiogalactopyrano-
side (IPTG) and deactivated by anhydrotetracycline (aTc; Gardner et al., 
2000). The LacI and TetR repressor proteins bind the Ptrc-2 and PLtetO-1 pro-
moters, respectively. (C) In the mammalian toggle switch, secreted alkaline 
phosphatase (SEAP) output is activated erythromycin (EM) and deactivated 
by pristinamycin I (PI; Kramer et al., 2004). Repressor proteins, containing 
the KRAB (Kruppel-associated box) transcription repression domain fused 
with either the pristinamycin-induced transcription regulator protein (PIP) 
or the macrolide responsive MphR(A) protein (E) bind to promoters con-
taining a simian virus 40 region (PSV40) and target sequences for PIP (PIR) 
or E (ETR).591 Eukaryotic synthetic biology • Haynes and Silver
in the presence or absence of specific small molecules (for 
review see Weber and Fussenegger, 2006).
Natural cellular processes such as differentiation have been 
emulated by synthetic transcription­based systems. Differentiation 
occurs within a homogenous population when a subset of cells 
experience a transient stimulus, trigger a switch in cellular physi­
ology, and this change is maintained through mitosis in the cell 
lineage. Synthetic self­activating genes conferring long­term cel­
lular memory have been constructed and tested in yeast (Becskei 
et al., 2001, Ajo­Franklin et al., 2007). Ajo­Franklin et al. (2007) 
used rational engineering to build a synthetic positive feedback 
system that converted a transient stimulus into sustained tran­
scriptional activation. An inducible promoter (sensor) was designed 
to stimulate a two­gene circuit in which an ATF triggered a self­
activating gene (Fig. 2 C). First, the Hill parameters (basal and 
maximal production rates, Hill cooperativity, and the concentra­
tion at half­maximum activity) were measured for two different 
ATFs in dividing cells. Then model circuits were tested in silico 
to determine which ATF would allow switch­like and sustained 
activation. As predicted by math modeling, the unsuitable ATF 
locked the gene circuit in the active state, whereas the suitable 
ATF allowed switching from an uninduced state to gene expres­
sion that remained active over several cell divisions.
Customizable control of protein production. 
Translation is an attractive target for direct and tight regulation of 
protein concentrations. Synthetic biology achieves translational 
receptors were transferred to yeast pathways demonstrates the 
modularity of transmembrane sensors in eukaryotes (Strader   
et al., 1991; for review see Pausch, 1997). Since then, protein en­
gineering via mutagenesis has produced a collection of “receptors 
activated solely by synthetic ligands” (RASSLs), which expands 
the number and variety of potential input stimuli for synthetic 
signaling circuits (for review see Conklin et al., 2008). Constitutive 
and deleterious stimulation observed in some RASSL systems 
could be fine­tuned by synthetic auto­regulatory circuits similar 
to the ones developed in yeast.
Synthetic  regulation  of  gene  transcription. 
Gene regulation is a key end point for signal processing in liv­
ing cells. Foundational work in molecular biology, such as the 
elucidation of the bacterial lac gene regulation system (Jacob 
and Monod, 1961), established a paradigm for genetic switches 
(for review see Wilson et al., 2007); an input signal modulates 
the binding of transcriptional regulator proteins at DNA dock­
ing sites near gene promoters, conferring a gene activity state 
(i.e., on or off). Following this design, artificial transcription 
factors (ATFs) consist of a protein domain, which binds to a 
specific DNA element near a minimal promoter, tethered to an 
effector domain (e.g., an activator or repressor) that regulates 
transcription. DNA binding domains, such as Gal4, lexA, and 
zinc finger motifs, are used to create locus­specific ATFs. Con­
trol of ATF function has also been accomplished with DNA 
binding domains that interact with their target sequences either 
Figure 2.  Three levels of modular functions within synthetic devices. (A) An input signal, such as a small molecule, ligand, or metabolite, is detected at 
the sensor level. The signal is then translated into a pattern of behavior at the circuit level. At the output level, reporter gene expression and/or effectors of 
downstream processes coincide with the behavior of the circuit. Each box lists examples of sensors, circuits, and outputs that are correspondingly shaded in 
B–D. (B) In a cell signaling–based device, pheromone input binds a receptor and triggers an engineered MAPK signal circuit that activates GFP expression 
and the negative regulator Msg5. Activation, negative feedback, then deactivation result in a burst of GFP output (Bashor et al., 2008). (C) In a transcription-
based device, transient galactose input induces the expression of a PGAL1-driven ATF that initiates the stable transcription of a positive feedback gene and 
sustained YFP output (Ajo-Franklin et al., 2007). (D) Functions of a riboswitch are encoded within folded RNA domains. Theophylline input binds to the 
aptamer sensor region, causing a conformational change that is transduced down the molecule to disrupt ribozyme-mediated RNA cleavage and allow 
GFP expression (Win and Smolke 2007, 2008).JCB • VOLUME 187 • NUMBER 5 • 2009   592
interfacing synthetic device output with a cellular target, such 
as an endogenous gene, mRNA, or protein (Fig. 3 B). Successes 
in  manipulating  cytoskeletal,  genetic,  and  physiological  re­
sponses (Deans et al., 2007; Yeh et al., 2007; Mody et al., 2009) 
indicate progress toward interfacing synthetic systems with 
endogenous mechanisms. Guanine nucleotide exchange factors 
(GEFs) have been engineered to convert forskolin­induced pro­
tein kinase A (PKA) activation into cytoskeletal reorganization 
in mammalian cells (Yeh et al., 2007). In this study, a PKA­
regulated protein domain was fused with a protein module that 
activated either Cdc42 or Rac1 GTPases, which induced broad 
membrane ruffles or thin spiked protrusions, respectively. The 
following discussion highlights examples of regulatory systems 
control by two strategies. First, RNA interference (RNAi) is used 
to fine­tune expression dynamics of transcription based systems 
(Deans et al., 2007; Greber et al., 2008; Tigges et al., 2009). 
Second, RNAi and functional RNAs are used as the basis for cir­
cuit behavior such as switch control and multiple input process­
ing (Yen et al., 2004; Bayer and Smolke, 2005; Rinaudo et al., 
2007; Win and Smolke, 2007, 2008; Beisel et al., 2008).
RNAi is mediated by sequence complementarity, allowing 
virtually any target messenger RNA (mRNA) to be silenced by 
custom­built sequences. A short interfering RNA (siRNA) 
or microRNA (miRNA), encoded in the transcript of a gene, 
targets the corresponding sequence of another transcript for 
degradation (via siRNA) or inhibition of translation (via miRNA). 
Synthetic biology researchers have used RNAi to reduce basal 
transcription, tightening control of synthetic gene networks (Deans 
et al., 2007; Greber et al., 2008). Deans et al. (2007) designed a 
modular  IPTG­inducible  switch  that  produces  short  hairpin 
RNAs (shRNAs) to prevent leaky expression of toxic transgenes 
in human and CHO cells. Greber et al. (2008) have recently 
proposed a general strategy in which intronic siRNAs diminish 
basal gene expression in the off state of inducible transcription 
systems and synthetic circuits.
In other synthetic devices, RNAi­based translational regu­
lation serves as the pivotal function rather than a means to opti­
mize performance. Synthetic ribozymes are functional RNA­based 
devices that mediate chemically induced mRNA self­cleavage in 
mammalian and yeast cells (Yen et al., 2004; Win and Smolke, 
2007, 2008). “Antiswitch” (Bayer and Smolke, 2005) and “shRNA 
switch” (Beisel et al., 2008) systems control translation by regu­
lated RNA duplex formation. Ribozymes, antiswitches, and shRNA 
switches contain an aptamer (sensor) module that specifically 
binds to a single small molecule, causing an allosteric modifica­
tion that is propagated through a “transducer” module. Altered 
RNA folding of the device either permits or blocks translation of 
a target mRNA molecule that encodes a visible output signal 
(Fig. 2 D). Other RNAi­based synthetic devices can process com­
binations of inputs using Boolean logic. Ribozyme switches have 
been fitted with multiple aptamers to process the presence or ab­
sence of two small molecules in yeast (Win and Smolke, 2008). 
Rinaudo et al. (2007) designed a mammalian logic evaluator 
composed of genes with multiple RNAi target sequences in the 
3­untranslated region of each mRNA transcript. Fluorescent pro­
tein output in human kidney cell culture showed that the gene cir­
cuit correctly evaluated combinations of up to five transfected 
siRNA inputs. Modified systems in which ribozyme switches me­
diate the mammalian circuit will enable the detection of multiple 
chemical signals as well as siRNAs. Future efforts to engineer logic 
circuits that evaluate endogenous cellular inputs will lead the way 
to synthetic devices that can sense and correctly respond to com­
plex physiological conditions.
Interfacing synthetic circuits with natural 
cellular processes
Engineering a synthetic device to sense changes in the inter­
cellular environment (Fig. 3 A) synchronizes a visible reporter, 
and potentially a therapeutic product, with developmental and 
disease states. Conversely, devices can regulate cell behavior by 
Figure 3.  Interfacing synthetic circuits with biological functions. (A) Syn-
thetic devices can be placed under the control of sensors that sense inputs 
such as transcription factors, metabolites (Table I), and potentially miRNAs. 
In a population of cells that carry the circuit, the cell (shaded blue) that 
expresses certain developmental or disease cues triggers activity of the 
circuit. (B) At the output level, synthetic devices can be interfaced with 
cell phenotypes by placing endogenous targets under the control of circuit 
outputs: transcription factors target endogenous genes, small RNA silenc-
ers  target  transcripts,  and  guanine  nucleotide  exchange  factors  target 
GTPase enzymes that regulate cytoskeletal morphology. Consequently, all 
cells (shaded blue) that are exposed to the input stimulus undergo a pro-
grammed change in phenotype.593 Eukaryotic synthetic biology • Haynes and Silver
Using the complexity of eukaryotic cells  
to create novel functions
Subcellular localization and compartmentalization. 
Modular parts have been used to control the subcellular location 
of proteins and nucleic acids, enhancing proper assembly and 
function of synthetic devices. The signaling circuit developed 
by Bashor et al. (2008) exemplifies the effectiveness of cell 
membrane–bound protein scaffolds in controlling protein position­
ing, interactions, and circuit dynamics. Nuclear transport is 
commonly mediated by the SV40 nuclear localization sequence 
(NLS; Kalderon et al., 1984; Lanford and Butel, 1984) to enable 
ATFs to reach their gene targets. Other NLSs (McLane and 
Corbett, 2009) and nuclear export signals (NESs; Fischer et al., 
1995; la Cour et al., 2003) with distinct translocation dynamics 
could be explored as ways to alter nuclear transport of synthetic 
device components. The mitochondria and ER have been used as 
localization sites for synthetic proteins tagged with Tom70 and 
Ubc6 peptides (Kornmann et al., 2009). Localization not only 
enhances synthetic device function, but can also define functional 
states. For instance, farnesylation­mediated positioning regu­
lates a synthetic translation factor consisting of the eIF4G trans­
lation initiation factor, a viral RNA­binding domain, and a 
plasma membrane–targeting CAAX motif (Boutonnet et al., 2004). 
Inhibition of farnesylation releases the translation factor from the 
cell membrane, allowing it to specifically bind and translate 
mRNAs that contain a 21­nucleotide recognition site.
Toward controlling cell morphology. Manipulating 
whole­cell morphology underlies the vision to build increas­
ingly  sophisticated  synthetic  systems  that  control  important 
physiological processes. An initial step toward this aim is the 
use of synthetic signaling pathways to control distinct morpho­
logical changes in mammalian cells (Yeh et al., 2007; Levskaya 
et al., 2009). The realization of ambitions such as programmed 
cell  differentiation  and  engineered  cell  motility  may  benefit 
from exploring cell polarity mechanisms that might be amena­
ble to engineering. Cell polarity is established by asymmetrical 
distributions of mRNA and proteins during interphase and be­
fore cell division. Transcripts containing localization sequences, 
or “zipcodes,” are actively sorted in the cytoplasm for localized 
translation  and  protein  function  (for  review  see  Paquin  and 
Chartrand, 2008). RNA zipcodes suggest an approach for design­
ing addressable synthetic mRNA molecules. Additionally, exam­
ples of rationally designed mRNA localization and transcription 
and strategies that could be used to couple cellular processes 
with synthetic devices at the sensor and output levels.
Inducible promoters serve as sensors in most transcription­
based synthetic devices. Several artificial inducible transcription 
systems respond to endogenous physiological cues (for review see 
Weber and Fussenegger, 2006), including hormones (Webster   
et al., 1988; Braselmann et al., 1993), hypoxia (Tang et al., 2005), 
and low nutrient level–associated NADH depletion (Weber et al., 
2006). In these systems, a signal­responsive transcription factor is 
fused to a DNA binding domain (e.g., Gal4) that binds to synthetic 
regulatory elements upstream of a minimal promoter and target 
gene (Table I). Sensors can also be built by assembling minimal 
promoters with natural regulatory DNA elements that are induced 
by endogenous transcription factors that respond to various stim­
uli (Strähle et al., 1987; Elledge and Davis, 1989; Ohno et al., 
2008; Meijsing et al., 2009; for review see Guo et al., 2008). The 
cellular metabolite thiamine pyrophosphate (TPP) is sensed by 
synthetic riboswitches (Nomura and Yokobayashi, 2007; Yamauchi 
et al., 2008; Wieland et al., 2009). Other metabolites, including 
adenine, vitamin B12, flavin mononucleotide, and many others (for 
review see Blouin et al., 2009) remain to be tapped for riboswitch 
engineering. Development and disease­associated miRNAs are 
another potential input signal for synthetic systems (Brown et al., 
2007). Plausibly, a complimentary target RNA sequence could be 
incorporated into the untranslated region of a repressor gene that 
holds a synthetic circuit in an off state. It would be interesting to 
see whether silencing of the repressor and activation of the device 
can reliably report miRNA expression in developing cells.
Cell phenotypes can be regulated by synthetic circuit outputs 
that target endogenous genes and proteins (Fig. 3 B). In plants, 
RNAi knock­down and overexpression of a small set of endoge­
nous genes leads to visible rapid depletion and restoration of chlo­
rophyll (Antunes et al., 2006). These genes could be placed under 
the control of chemical­sensing circuits to create a living sentinel 
system for environmental hazards (Bowen et al., 2008). ATFs that 
contain Cys2­His2–type zinc­finger DNA binding domains have 
been targeted to specific mammalian genes (Sera, 2009), including 
the anti­angiogenic pigment epithelium derived factor (PEDF; 
Yokoi et al., 2007), utrophin (Desantis et al., 2009), and the breast 
tumor suppressor maspin (Beltran et al., 2007, 2008). Developing 
synthetic devices that produce gene­specific ATFs, siRNAs, and 
miRNAs may lead to innovative synthetic tools with significant im­
pacts in environmental safety, experimental biology, and therapy.
Table I. Endogenous eukaryotic signals that stimulate synthetic sensors
Input signal Synthetic sensor Sensor function
Estrogen ATF: Gal4 (DBD), estrogen receptor (TAD) (Webster et al., 1988; 
Braselmann et al., 1993)
Transcription activation at the Gal4 element
Hypoxia ATF: Gal4 (DBD), HIF-1 oxygen-dependent degradation domain,  
  p65 (TAD) (Tang et al., 2005)
Transcription activation at the Gal4 element
l-arginine synthesis ATF: ArgR (DBD), VP16 (TAD) (Hartenbach et al., 2007) Transcription activation at the ARG box element
NADH depletion  
(low nutrient levels)
ATF: REX (DBD), VP16 (TAD) (Weber et al., 2006) Transcription activation at the ROP element
Thiamine pyrophosphate Riboswitch: thiamine pyrophosphate (TPP) aptamer  
  (Nomura and Yokobayashi, 2007; Yamauchi et al., 2008;  
  Wieland et al., 2009)
Translation control via mRNA cleavage
Artificial transcription factor (ATF) fusion proteins and a synthetic riboswitch are described here. DBD = DNA binding domain; TAD = transcription activation domain.JCB • VOLUME 187 • NUMBER 5 • 2009   594
circadian clock models provide a system for future studies to re­
solve the impact of other factors, such as post­translational protein 
modification, on circadian oscillation.
Implications for advances in medicine. To date, a 
small number of direct contributions to medicine have emerged 
from advances in synthetic biology. Synthetic biology has been 
applied to the cost­effective production of an antimalarial drug 
precursor in yeast and bacteria (Ro et al., 2006; Anthony et al., 
2009) and a new drug­screening technology in human cell cul­
ture (Weber et al., 2008). The latter effort focused on combating 
drug­resistant strains of Mycobacterium tuberculosis in which 
EthR represses ethA, a gene required for activation of the drug 
ethionamide. A synthetic system, in which EthR induced re­
porter gene activation in human cells, was used to identify non­
cytotoxic drugs that could cross the cell membrane and disrupt 
EthR function (Weber et al., 2008).
In  developing  therapeutic  synthetic  devices  for  human 
cells, it is crucial to anticipate potentially dangerous off­target 
effects and host cell gene disruption. One solution is to design 
synthetic devices that operate outside of human cells. To this 
end, E. coli have been engineered to carry a gene circuit that 
senses tumor­associated cues (i.e., hypoxia and bacterial aggre­
gation near tumors) and expresses invasin, a protein that allows 
bacteria to enter mammalian cells (Anderson et al., 2006). Link­
ing cytotoxin production with cell invasion will result in a pro­
biotic strain that can seek out and destroy tumors. Still, creating 
human cells that secrete therapeutic products or regenerate tis­
sues in a programmable way are attractive and powerful ap­
proaches to therapy. Tight artificial control of genes in response 
to combinatorial signals could allow tissue­ and disease­specific 
expression and decrease toxicity. Furthermore, synthetic gene 
circuits that produce therapeutic products could translate a tem­
porary dose of input signal into sustained output, circumventing 
the need for sustained and potentially toxic drug administration.
Current challenges and concluding remarks
Developing a large pool of quantitatively annotated, reliable, and 
modular biological parts could enhance progress in designing 
synthetic eukaryotic systems. Potentially, a multitude of novel 
parts can be culled from natural systems, built de novo based on 
evolutionarily conserved motifs, or generated by mutagenesis. 
Thorough testing of new modules is an important step in con­
structing functional systems. For instance, undesirable and un­
expected performance of computer­designed zinc­finger modules 
(Ramirez et al., 2008) underscores the need for efficient ways 
to characterize in vivo libraries of putative new ATFs. Other 
reviews detail strategies to address the challenge of developing 
reliable standardized parts (for reviews see Andrianantoandro 
et al., 2006; Heinemann and Panke, 2006).
Synthetic biology researchers using eukaryotic systems 
should also consider the importance of stably integrating devices 
into the host cell genome. Expression of synthetic assemblies 
from transiently transfected plasmids is often used to quantify de­
vice behavior. For example, plasmid dosage of a synthetic circa­
dian circuit (Tigges et al., 2009) appeared to influence the behavior 
of the device in some cells, but plasmid copy number variability 
from cell to cell cannot be directly determined. Stable transgene 
(Boutonnet et al., 2004) as well as scaffold­mediated protein 
activity (Bashor et al., 2008) may serve as a foundation for pro­
grammable cell polarity.
Contributions of synthetic biology to cell 
biology research and medicine
Synthetic  biology  as  a  research  paradigm? Con­
struction and testing of synthetic devices in living cells can 
provide insight into cell biology by determining whether our 
mechanistic models can sufficiently describe natural systems 
or if there are still gaps in our understanding. In the context of 
research discovery, rational assembly of parts accomplishes 
three objectives: placing biological components into new con­
texts that may reveal previously unobserved characteristics, 
generating tools for analysis in vivo, and testing previously 
established models by reconstruction.
When device construction is guided by an engineering 
aim rather than a research goal, biological components are often 
juxtaposed in unique ways. Unexpected behavior of the syn­
thetic device can reveal previously unknown characteristics of 
one or more components. Although it might be considered a 
setback to the synthetic device engineer, this type of outcome 
can spur important investigative research that enhances the body 
of scientific knowledge (Haynes et al., 2008).
In some cases, fusion proteins and synthetic circuits are 
designed as probes for studying molecular dynamics within living 
cells. Fusion proteins that artificially link cellular functions have 
been used in screens to probe phenotypes that are not accessible 
by more conventional genetic dissection (Sadler et al., 1989; 
Stirling et al., 1992; Kornmann et al., 2009). Kornmann et al. 
(2009) used a synthetic ER–mitochondria tethering protein to 
rescue a panel of mutations, allowing the identification of elusive 
natural components of ER–mitochondrial tethering in yeast. In a 
study of transcription dynamics, a synthetic circuit was used to 
directly test the hypothesis that long introns affect eukaryotic 
gene expression by increasing transcription elongation time (for 
review see Swinburne and Silver, 2008). Increased intron lengths 
within  a  self­inhibitory  gene  were  accompanied  by  delayed 
pulses of protein expression in mouse cells (Swinburne et al., 
2008). The genetic switch developed by Deans et al. (2007) al­
lowed their group to observe the impact of graded bax gene in­
duction on apoptosis. The results of this study indicate a possible 
high threshold level for Bax­induced death in mammalian cells.
Synthetic systems provide a simplified, well­defined frame­
work for testing models of fundamental biological processes by 
reconstruction. The sufficiency of positive feedback to establish 
bistability, a property of cell cycle progression, has been demon­
strated using synthetic circuits based on transcription and protein 
interactions (e.g., Becskei et al., 2001; Ingolia and Murray, 2007). 
Basic mechanisms underlying circadian oscillation have also been 
investigated using synthetic models (Ukai­Tadenuma et al., 2008; 
Tigges et al., 2009). Two natural phases of the circadian clock, 
daytime and nighttime expression, were reconstructed using arti­
ficial transcription activators and repressors under the control of 
endogenous clock–controlled DNA sequences. This outcome in­
dicates that transcriptional regulation is a sufficient mechanism 
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integration is a more reliable approach for altering and observing 
the impact of gene dosage in proliferating engineered cell popula­
tions (Ajo­Franklin et al., 2007).
As synthetic biology moves toward introducing more com­
plex genetic systems into eukaryotic cells, tools should be de­
veloped to facilitate the manipulation of eukaryotic systems. 
Reproducible integration of synthetic devices and replacement of 
damaged devices could be accomplished using transgenic cells 
and organisms that carry standard integration sites (e.g., the Flp/
FRT system from yeast). Additionally, insulator elements such as 
cHS4 (Yahata et al., 2007; Hanawa et al., 2009) could be used to 
shield synthetic genes from transcriptional perturbations and dis­
ruptive chromatin packaging. Mathematical modeling could be 
used to identify which eukaryotic cell features might have a sig­
nificant impact on synthetic devices. Modeling the effect of large 
cytoplasmic and nuclear volumes, diffusion perturbed by mem­
brane boundaries, and the likelihood of random nontarget ATF 
binding sites in large genomes may help to identify areas of focus 
for optimization of eukaryotic synthetic systems.
Synthetic biology research accomplishments thus far have 
demonstrated  that  custom­built  systems  can  function  within 
complex intercellular environments without being significantly 
hampered by unknown factors. Furthermore, eukaryotic path­
ways such as signaling cascades, nuclear transport, and sub­
cellular localization can be harnessed to create circuits with 
diverse topologies. Unexplored eukaryotic cell components and 
pathways present a vast landscape with extensive potential for 
ongoing work in synthetic biology.
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